Day: May 6, 2025

1Q 2025 Total revenue grew 15% year-over-year to $52.2 million driven by 33% year-over-year growth in Payor revenue 1Q 2025 Net income of $0.3 million and adjusted EBITDA1 of $2.0 million 1Q 2025 Share repurchases of $7.0 million NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) — Talkspace, Inc. (“Talkspace” or the “Company”) (NASDAQ: TALK), today reported first quarter 2025 financial results.    Three Months Ended March 31, 2025         Unaudited   Results   % Variance fromPrior Year  (In thousands unless otherwise noted)          Number of completed Payor sessions during the period     350.0     23%  Number of Unique Active Payor members during the period     101.2     17%             Total revenue   $ 52,182     15%  Gross profit   $ 23,281     7%  Gross margin %     44.6%      Operating expenses   $ 24,366     4%  Net...

— Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data — Expansion of the Company’s PI3Ka franchise with the planned announcement of a pan-mutant selective development candidate in Q2 2025 — $96.7M in cash and cash equivalents expected to be sufficient to fund operations through multiple anticipated milestones into Q4 2026 BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) — OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the quarter ended March 31, 2025, and provided business highlights. “OnKure looks to define a new standard of performance for precision targeted agents....

‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights:CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialysis customers. The Company’s first quarter of 2025 was profitable and cash flow positive, with net income of $20.6 million, adjusted EBITDA of $23.6 million, and cash from operations of $19.7 million. The...

– Favorable clinical data in PD-(L)1 resistant patients – – Dose expansion enrollment complete with full data expected by year-end 2025 – – Cash runway into the second quarter of 2026 – BOSTON, May 06, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. “This was a breakthrough quarter for Sensei,” said John Celebi, President and CEO. “We observed favorable signs of clinical activity in patients with PD-(L)1-resistant cancers from our dose expansion cohort—patients who face poor odds and few options. Beyond the responses we have observed, what’s striking...

MOUNT LAUREL, N.J., May 06, 2025 (GLOBE NEWSWIRE) — J & J Snack Foods Corp. (NASDAQ: JJSF) (the “Company”) today reported financial results for the second quarter ended March 29, 2025.    Second QuarterActuals $ vs. LY % vs. LYNet Sales $356.1M ($3.6M) (1%)Gross Profit $95.7M ($12.5M) (12%)Operating Income $6.0M ($11.9M) (66%)Net Earnings $4.8M ($8.5M) (64%)Earnings per Diluted Share $0.25 ($0.44) (64%)       Adjusted Operating Income $8.9M ($13.0M) (59%)Adjusted EBITDA $26.2M ($13.1M) (33%)Adjusted Earnings per Diluted Share $0.35 ($0.49) (58%)This press release contains non-GAAP financial measures. Please refer to the Non-GAAP Financial Measures section below for reconciliations to the most comparable GAAP measures. Dan Fachner, J&J Snack Foods Chairman, President, and CEO stated,...